Soligenix SNGXW 深 沪
已收盘 12-15 16:00:00 美东时间
0.009
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 0.009
- 总市值 36.02万
- 52周最高 0.82
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.008
- 委 比 0.00%
- 总股本 4002.05万
- 历史最高 1.314
- 量 比 0
- 振 幅 0.00%
- 历史最低 0.00
- 每 手 1
- 风险率 0.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Soligenix GAAP EPS of $0.28
Soligenix press release (SNGX): Q1 GAAP EPS of $0.28. Research and development expenses were $1.8 million as compared to $1.9 million for the quarter ended March 31, 2026 and 2025, respectively. The d...
05-08 19:44
Soligenix Q1 EPS $(0.28), Inline
Soligenix (NASDAQ:SNGX) reported quarterly losses of $(0.28) per share which met the analyst consensus estimate. This is a 73.58 percent increase over losses of $(1.06) per share from the same period last year.
05-08 19:38
Why Is Soligenix Stock Sinking Tuesday?
Soligenix ends Phase 3 FLASH2 study for HyBryte. CEO cites unanticipated results. See how this impacts SNGX and next steps.
04-28 21:56
The Data Monitoring Committee Recommends Soligenix To Halt Phase 3 FLASH2 Trial Of HyBryte (Synthetic Hypericin) For Cutaneous T-cell lymphoma For Futility
Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced
04-28 19:33
Soligenix (NASDAQ: SNGX) Highlights Patient-Centric Drug Development Strategy Through Reformulation Approach
Austin, Texas, United States, April 21st, 2026, FinanceWire By Christopher J. S...
04-22 00:00
Soligenix (NASDAQ: SNGX) Advances CTCL Research with Interim Analysis, Comparative Study Results
Austin, Texas, United States, April 17th, 2026, FinanceWire Soligenix reports c...
04-18 01:30
Soligenix (NASDAQ: SNGX) Publishes Positive HyBryte Study Results In Oncology and Therapy
Austin, Texas, United States, April 2nd, 2026, FinanceWire Soligenix(NASD...
04-03 00:00
Soligenix Q4 EPS $(0.29) Beats $(0.56) Estimate
Soligenix (NASDAQ:SNGX) reported quarterly losses of $(0.29) per share which beat the analyst consensus estimate of $(0.56) by 48.75 percent. This is a 74.82 percent increase over losses of $(1.14) per share from the
04-01 13:20
Soligenix Secures EU Orphan Drug Status For Rare Disease Treatment, Designation Provides 10-Year Market Exclusivity And Development Support
Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced
03-26 19:36
Soligenix (NASDAQ: SNGX) HyBryte Data To Be Presented At USCLC Workshop Ahead Of AAD Meeting
Austin, Texas, United States, March 24th, 2026, FinanceWire Soligenix(NAS...
03-25 00:30
